Resources
13 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 6/10/2022 (updated 3/27/2024)
More people are dying from overdose now than at any point in history. Individuals learned about three innovative communication campaigns that challenge stigma, center people who use drugs, and build support for harm reduction as a lifesaving strategy to reduce overdose deaths.
Posted 6/3/2022 (updated 3/27/2024)
During this session, Dr. Lopata discussed federal/HRSA investments focused on improving the health outcomes for and reducing health disparities among maternal and child health populations. More specifically, Dr. Lopata discussed the multiple programs/interventions funded by HRSA that together work (along with federal, state, regional, and local partners) to improve the prevention, screening, and treatment of opioid use disorder during pregnancy and Neonatal Abstinence Syndrome in the United States.
Posted 6/7/2022 (updated 3/27/2024)
Cohort-Specific Sessions/Activities and Day 2 Wrap-Up
Posted 6/15/2020 (updated 3/28/2024)
The Opioid Use Disorder, Pregnant Women and Neonatal Abstinence Syndrome (NAS): Addressing the Challenges (Part II) webinar took place on June 9, 2020.
Posted 9/18/2020 (updated 3/29/2024)
The National Alliance of State and Territorial AIDS Directors (NASTAD) hosted the Hepatitis A and Hepatitis B Vaccination Efforts in People Who Inject Drugs webinar last week, September 10, 2020. The session featured Centers for Disease Control and Prevention subject matter experts who discussed the epidemiology of hepatitis A and hepatitis B in people who use and inject drugs and the rationale for the vaccination recommendations. The session also featured several jurisdictions and partner organizations who shared their lessons learned and best practices for reaching and implementing vaccination services in this community.
Posted 6/30/2021 (updated 4/2/2024)
This guidance publication is intended to support the efforts of states, tribes, and local communities in addressing the needs of pregnant women with opioid use disorders and their infants and families. National data show that from 2000 to 2009 the use of opioids during pregnancy increased from 1.19 to 5.63 per 1,000 hospital births (Patrick, Schumacher, Benneyworth, Krans, McAllister, & Davis, 2012). Because of the high rate of opioid use and misuse among all women, including pregnant women, medical, social service, and judicial agencies are having to confront this concern more often and, in some communities, at alarming rates.
This guidance document provides background information on the treatment of pregnant women with opioid use disorders, summarizes key aspects of guidelines that have been adopted by professional organizations across many of the disciplines, presents a comprehensive framework to organize these efforts in communities, and provides a collaborative practice guide for community planning to improve outcomes for these families. A set of appendices provides details on implementing the recommendations in the guide as well as a summary of lessons from one community’s experience over the past decade.
Posted 8/4/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Posted 2/23/2021 (updated 4/4/2024)
RCORP Planning 3 Reference Guide
Posted 3/25/2021 (updated 4/5/2024)
Effective Harm Reduction Strategies for People Who Actively Use Opioids and/or Psychostimulants
Participants will learn evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters will discuss methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.